Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Horn, Leora, Wang, Ziping, Wu, Gang, Poddubskaya, Elena, Mok, Tony, Reck, Martin, Wakelee, Heather, Chiappori, Alberto A, Lee, Dae Ho, Breder, Valeriy, Orlov, Sergey, Cicin, Irfan, Cheng, Ying, Liu, Yunpeng, Fan, Yun, Whisenant, Jennifer G, Zhou, Yi, Oertel, Vance, Harrow, Kim, Liang, Chris, Mao, Li, Selvaggi, Giovanni, Wu, Yi-Long
Published in JAMA oncology (01.11.2021)
Published in JAMA oncology (01.11.2021)
Get more information
Journal Article
eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Horn, Leora, Wu, Yi-Long, Reck, Martin, Liang, Chris, Tan, Fenlai, Harrow, Kimberly, Oertel, Vance, Dukart, Gary, Mok, Tony
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
Horn, Leora, Wu, Yi-Long, Reck, Martin, Wakelee, Heather A., Liang, Chris, Tan, Fenlai, Harrow, Kimberly, Oertel, Vance, Dukart, Gary, Mok, Tony
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article